Literature DB >> 8735547

Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL.

B Deprez1, J P Sauzet, C Boutillon, F Martinon, A Tartar, C Sergheraert, J G Guillet, E Gomard, H Gras-Masse.   

Abstract

We have previously shown that virus-specific CTL responses can be elicited in vivo by injecting, without adjuvant, 12-40 amino acid-long peptides, modified in C-terminal position by a simple lipidic amino acid. In this paper, we have studied the chemical accessibility, and the ability to induce in mice a CTL response, of a series of lipopeptides derived from the HIV-1 env (312-327) or (302-335) sequences. We showed that a single modification of these peptides by a lipidic amino acid, preferably in C-terminal position, results in the ability to reproducibly induce, without adjuvant, a relevant CTL response. No clear discrimination appeared concerning the nature of the lipidic modification. Our findings indicate that modification of a relatively long peptide by a N epsilon-palmitoyl-L-Lysylamide can be achieved by conventional methods of synthesis and characterization, offering the possibility to develop low-cost synthetic vaccines in models in which the CTL component is of importance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8735547     DOI: 10.1016/0264-410x(95)00220-u

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Type 1 CD4(+) T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques.

Authors:  L Mortara; H Gras-Masse; C Rommens; A Venet; J G Guillet; I Bourgault-Villada
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine.

Authors:  L Mortara; F Letourneur; H Gras-Masse; A Venet; J G Guillet; I Bourgault-Villada
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

3.  Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus.

Authors:  Georgia Deliyannis; David C Jackson; Nicholas J Ede; Weiguang Zeng; Irene Hourdakis; Evaline Sakabetis; Lorena E Brown
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 4.  TLR-based immune adjuvants.

Authors:  Folkert Steinhagen; Takeshi Kinjo; Christian Bode; Dennis M Klinman
Journal:  Vaccine       Date:  2010-08-14       Impact factor: 3.641

Review 5.  New concepts in herpes simplex virus vaccine development: notes from the battlefield.

Authors:  Gargi Dasgupta; Aziz A Chentoufi; Anthony B Nesburn; Steven L Wechsler; Lbachir BenMohamed
Journal:  Expert Rev Vaccines       Date:  2009-08       Impact factor: 5.217

Review 6.  Human immunodeficiency virus vaccine trials.

Authors:  Robert J O'Connell; Jerome H Kim; Lawrence Corey; Nelson L Michael
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

7.  SIV escape mutants in rhesus macaques vaccinated with NEF-derived lipopeptides and challenged with pathogenic SIVmac251.

Authors:  Pascale Villefroy; Franck Letourneur; Zoe Coutsinos; Lorenzo Mortara; Christian Beyer; Helene Gras-Masse; Jean-Gerard Guillet; Isabelle Bourgault-Villada
Journal:  Virol J       Date:  2006-08-31       Impact factor: 4.099

Review 8.  Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands.

Authors:  Deana N Toussi; Paola Massari
Journal:  Vaccines (Basel)       Date:  2014-04-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.